BioWorld - Wednesday, February 4, 2026

BioWorld Science

March 12, 2020

View Archived Issues

Unexpected mechanism, combination possibilities for CDK4/6 inhibitors

Read More

In SIV infection, gut integrity is retained, not repaired

Read More

Stromal FOXC1 and tumoral ERK1-2, p38 as prognostic biomarkers in DLBCL

Read More

A panel of markers found to distinguish thymomas from thymic carcinomas

Read More

Scale-up synthesis and characterization of a TRPV1 agonist with strong topical analgesic activity

Read More

Transplantation of NSCs overexpressing Wnt4 shows preclinical utility for spinal cord injuries

Read More

New STAT3 inhibitor inhibits tumor growth and metastasis in preclinical models of colorectal cancer

Read More

Results from first-in-human study of [11C]SMW-139 as an in vivo neuroinflammation tracer in MS

Read More

Update on clinical development of opaganib

Read More

Safety and PK data presented for GS-9722

Read More

Phase I results for rectally administered microbicide gel formulated with IQP-0528

Read More

Aberrant DNA methylation predicts survival in acral melanoma

Read More

U.S. researchers present biodegradable implant for antiretroviral contraceptive delivery

Read More

Phase III GY004 study does not meet primary endpoint

Read More

Newave Pharmaceutical patents Bcl-2 inhibitors

Read More

Phase II study of MK-1454 and pembrolizumab in HNSCC initiated

Read More

Corvus Pharmaceuticals discloses adenosine receptor modulators

Read More

CANBERRA trial to evaluate RG-7774 in diabetic retinopathy

Read More

GlaxoSmithKline and ViiV Healthcare present compounds for HIV infection

Read More

Phase I/II trial of NEXI-001 underway in AML/MDS relapsing after hematopoietic cell transplant

Read More

Sunshine Lake Pharma discovers HBsAg inhibitors for HBV infections

Read More

New CD73 inhibitors presented by Eternity Bioscience

Read More

With Uhambo's and research lessons, once more unto the breach

Read More